

## PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES

December 13, 2016

The meeting was called to order at approximately 1:33 p.m. on Tuesday December 13, 2016.

Committee members present: Irina Petty, PA-C; Megan Keller, Pharm D; Megan Marchal, R.Ph.; Robert Zaayer, PA-C; Nancy Ivansek, PA-C; Curtis Gingrich, M.D., and Anita Steinbergh, D.O.

Staff members present: Sallie Debolt, and Cathy Hacker

### **I. Review of the November 8, 2016 minutes:**

It was noted that there was a typo in the minutes regarding Exondys it should read that the CTP may not prescribe.

Ms. Keller moved to approve the minutes as amended from the November 8, 2016 meeting. Ms. Petty seconded the motion. All members voted aye. The motion carried.

### **II. Review Formulary**

The committee discussed that the Federal rules regarding prescribing Buprenorphine are changing to allow for PA's and NP's to apply for a waiver to be allowed to prescribe this medication. Dr. Steinbergh recommended adding this to the formulary as CTP may prescribe so long as they have the required DEA waiver. It was noted that the use of this medication for analgesia remains CTP may prescribe and the Subcutaneous method would be PI as it requires the practitioner follow the patient every 30 days. It was requested that the formulary not be posted to the website until after 1/1/17 as that is when the Federal law takes effect.

Dr. Steinbergh notified the committee that even though the PAPC had recommended that Vivitrol be added to the formulary in 2014 as PI, the Board had yet to take action. She stated that it was being presented to them at this December meeting for a vote.

The committee reviewed the request from Dr. Arruda that is requesting for Tikosyn to be added to the formulary as PI. Dr. Steinbergh stated that she agreed with Dr. Arruda's request.

Dr. Steinbergh moved to put Tikosyn on the Formulary as PI. Dr. Gingrich seconded the motion. All members voted aye. The motion carried.

The committee had reviewed Xiidra at its November meeting and had recommended that it be added to the formulary as CTP may prescribe. Dr. Schachat disagreed with this decision at the November PA/Scope of practice meeting and requested that it be sent back to the PAPC for it to be put into the PI category. It was added to the formulary as LFA-1 antagonist under the PI category.

Dr. Steinbergh moved to approve this change. Ms. Keller seconded the motion. All members voted aye. The motion carried.

In a continuing effort to clean the formulary up mouthwashes and gargles were moved from the ophthalmology area to the gastrointestinal area.

***III. Negative Formulary discussion***

Dr. Steinbergh requested that the new negative formulary for the APNs be obtained for this committee to review.

***III. New business***

There was no new business discussed.

The Physician Assistant Policy Committee meeting was adjourned by Mr. Zaayer at approximately 2:18 p.m. on Tuesday, December 13, 2016.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on December 13, 2016.

---

Robert Zaayer, PA-C, Chair, PAPC